Traws Pharma
TRAW
22 hedge funds and large institutions have $3.86M invested in Traws Pharma in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
60% more capital invested
Capital invested by funds: $2.41M → $3.86M (+$1.45M)
24.31% more ownership
Funds ownership: 18.47% → 42.78% (+24%)
22% more funds holding
Funds holding: 18 → 22 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.44M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$890K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$433K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$343K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$70.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$278K |
| 2 |
HF
HRT Financial
New York
|
-$23K |
| 3 |
Citigroup
New York
|
-$7.84K |
| 4 |
Two Sigma Investments
New York
|
-$6.17K |
| 5 |
Morgan Stanley
New York
|
-$1.33K |
TRAW Hedge Fund Activity: Q4 2025 in Review
22 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2025, worth a combined $3.86M — up 60% from $2.41M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TRAW positions and 5 closed out — a net gain of 4 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $1.44M. The largest seller was Vestal Point Capital, exiting entirely with an estimated $278K sold.
- 22 institutional investors held Traws Pharma (TRAW) as of Q4 2025, up from 18 in Q3 2025.
- Funds reported $3.86M of Traws Pharma stock for Q4 2025, up 60% quarter-over-quarter.
- 9 funds opened new Traws Pharma positions in Q4 2025 and 5 closed out, a net change of +4 holders.
- The largest Traws Pharma buyer in Q4 2025 was Ikarian Capital, an estimated $1.44M added.
- The largest Traws Pharma seller in Q4 2025 was Vestal Point Capital, an estimated $278K sold.
Based on aggregated 13F filings for Q4 2025.